novo nordisk glp-1 weight loss glp 1 pill BREAKING: The FDA has approved the first oral for obesity, marking a major milestone in the weight-loss drug market and The FDA has issued a

Insights into the early use of oral semaglutide in routine clinical practice: the IGNITE study

Another example entails the established cardioprotective activity of GLP-1RAs,111 perhaps together with other helpful actions on brain perfusion as seen in the Cerebrovascular system and BBB dynamics section,50 which may have direct relevance to controlling risk factors such as hypertension and atherosclerosis,112 hence to the prevention of non-fatal stroke events and ultimately VaD.13 GLP-1RAs are also being investigated for the treatment of addiction, with preliminary evidence suggesting that they might be useful for reducing smoking57 113 and alcohol misuse114important risk factors for AD, alcohol-related dementia and other cognitive impairments.115 The development of novel GLP-1RAs could therefore be integrated with lifestyle interventions directly impacting key determinants of health116 to improve brain health and healthy ageing.117 Adverse events and other unwanted effects Studies thus far have broadly reported that GLP-1RAs display a benign safety profile,6 including in terms of adverse neuropsychiatric outcomes.17 Gastrointestinal symptoms, including nausea, bloating and sometimes vomiting, are the most common side effects, generally occurring during the first few weeks of taking the medications and subsiding with prolonged administrations.6 Some controversy remains regarding the relationship between these drugs and suicidality.118 Within the context of CNS disorders, pharmaceutical companies and researchers should also consider the development of GLP-1 agents that do not cause weight loss, especially of lean muscle massa peripheral effect that would be undesirable in frail older adults

A new study reports that of the 1 million new GLP-1 medication users identified between 2011 to 2023, there was a twofold increase in GLP-1 medication users who do not have type 2 diabetes

She told the BBC she did not realise the product was unlicensed and unregulated

doi: 10.1155/2024/4815488 222 LiuLLiJKeYZengXGaoJBaXet al